Stockscreener 앱 받기
48.84
0.91%
-0.45
시간 외 거래:
48.84
전일 마감가:
$49.29
열려 있는:
$49.07
하루 거래량:
559.20K
Relative Volume:
0.77
시가총액:
$2.81B
수익:
$718.95M
순이익/손실:
$-38.55M
주가수익비율:
-71.41
EPS:
-0.6839
순현금흐름:
$45.99M
1주 성능:
-3.21%
1개월 성능:
-4.89%
6개월 성능:
+6.08%
1년 성능:
+52.48%
1일 변동 폭
$48.56
$49.87
1주일 범위
$47.71
$51.81
52주 변동 폭
$29.16
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
48.84 | 2.84B | 718.95M | -38.55M | 45.99M | -0.6839 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 재개 | Jefferies | Buy |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 재개 | Jefferies | Hold |
| 2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-11-12 | 재확인 | B. Riley FBR | Buy |
| 2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
| 2017-10-19 | 개시 | FBR & Co. | Buy |
| 2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 개시 | Janney | Neutral |
| 2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2015-11-05 | 재확인 | Northland Capital | Outperform |
| 2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Quarterly Risk: Does Supernus Pharmaceuticals Inc have strong EBITDA margins2026 Technicals & High Accuracy Buy Signal Tips - baoquankhu1.vn
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Supernus Pharmaceuticals Q4 2025 earnings preview - MSN
SUPN (NASDAQ: SUPN) Form 144 lists 57,250-share resale after option exercise - Stock Titan
SUPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Supernus Pharmaceuticals CEO Sells $1.76M in Stock - National Today
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN
Insider Sell Alert: Frederick Hudson Sells Shares of Supernus Ph - GuruFocus
Supernus (NASDAQ: SUPN) CEO-linked KBT Trust sells 35,000 shares under 10b5-1 plan - Stock Titan
Director at Supernus (NASDAQ: SUPN) sells 5,369 shares - Stock Titan
SUPN SEC FilingsSupernus Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Mixed Short And Long Term Returns - simplywall.st
[144] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Insider sale of 5,369 shares at SUPN (NASDAQ: SUPN) - Stock Titan
Supernus Pharmaceuticals Stock Review: Valuation & Business Quality ConcernsNews and Statistics - IndexBox
3 Reasons SUPN is Risky and 1 Stock to Buy Instead - Yahoo Finance
Supernus at Barclays Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada
To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media
Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by Jefferies Financial Group Inc. - MarketBeat
Dimensional Fund Advisors LP Lowers Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus (NASDAQ: SUPN) CEO exercises performance units, withholds shares for taxes - Stock Titan
Supernus (SUPN) SVP Mottola sells shares after exercising 3,750 PSUs - Stock Titan
SUPERNUS (NASDAQ: SUPN) CFO exercises performance units, settles taxes in shares - Stock Titan
Supernus (NASDAQ: SUPN) SVP sells 8,877 shares after exercising 7,500 PSUs - Stock Titan
[Form 3] SUPERNUS PHARMACEUTICALS, INC. Initial Statement of Beneficial Ownership - Stock Titan
Precision Trading with Supernus Pharmaceuticals Inc. (SUPN) Risk Zones - Stock Traders Daily
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Victory Capital Management Inc. - MarketBeat
Victory Capital Management Reduces Stake in Supernus Pharmaceuticals - National Today
Insider Selling Alert: Georges Gemayel Sells Shares of Supernus Pharmaceuticals Inc (SUPN) - GuruFocus
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) Director Sells 10,000 Shares of Stock - MarketBeat
Form 144: Proposed sale of 4,438 shares by SUPN insider (SUPN) - Stock Titan
Director at Supernus (NASDAQ: SUPN) sells 18,787 shares of stock - Stock Titan
American Century Companies Inc. Decreases Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Recap Report: Is Supernus Pharmaceuticals Inc being accumulated by smart moneyTrade Analysis Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Buy" at Wall Street Zen - MarketBeat
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Q4 Results And 2026 Guidance Update - Sahm
B of A Securities Initiates Coverage of Supernus Pharmaceuticals (SUPN) with Buy Recommendation - MSN
Georges Gemayel sells shares under Rule 144 (SUPN) - Stock Titan
Citigroup Inc. Lowers Stake in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
GW&K Investment Management LLC Sells 184,268 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus (NASDAQ: SUPN) CFO receives performance share unit grant - Stock Titan
Supernus Pharmaceuticals (SUPN) CEO awarded 38,640 performance units - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP gets 3,750 performance share units - Stock Titan
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One-Year Surge? - simplywall.st
Supernus Pharmaceuticals (SUPN) Stock Analysis: A 14.66% Upside and Strong Buy Ratings Shape Investor Outlook - DirectorsTalk Interviews
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One Year Rally? - Yahoo Finance
Envestnet Asset Management Inc. Sells 63,513 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Supernus at TD Cowen Conference: Strategic Diversification Unveiled By Investing.com - Investing.com South Africa
Supernus at TD Cowen Conference: Strategic Diversification Unveiled - Investing.com
Supernus Pharmaceuticals (SUPN) Releases Q4 2025 Earnings: Revenue Up, Operating and Net Losses - Quiver Quantitative
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Supernus Pharmaceuticals Inc 주식 (SUPN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
2.02%
0.77%
자본화:
|
볼륨(24시간):